This Contract Manufacturing Pharma Stock Rises 33% in 1 Year: What Changed at the Jammu Plant

This contract manufacturing pharma stock rose approximately 33% in the twelve months to 17 September 2026, from a close of Rs 863.90 to Rs 1,150.10 on NSE. No split or bonus fell in that window, so the gain is pure price appreciation.

The company is Innova Captab Ltd (NSE: INNOVACAP), a Baddi-based formulations maker that builds medicines for other drug companies and sells its own brands. The Innova Captab share was among the stronger names on a screen of NSE small-cap stocks ranked by 1-year return, dated 17 September 2026, and the rally tracked one operating change at its new Jammu plant.

Click Here – Get Free Investment Predictions

How Much Has This Contract Manufacturing Pharma Stock Returned in 1 Year?

The verified return on this contract manufacturing pharma stock is 33.13%, from the Rs 863.90 close on 17 September 2025 to Rs 1,150.10 on 17 September 2026, when the Innova Captab share price closed 1.42% up.

The path was not smooth. This contract manufacturing pharma stock fell to an intraday low of Rs 622 on 2 March 2026, and almost the entire annual gain came after that low.

Period	Start Price (Rs)	Price on 17 Sep 2026 (Rs)	Return
1 Month	1,038.45 (17 Aug 2026)	1,150.10	10.75%
6 Months	709.85 (17 Mar 2026)	1,150.10	62.02%
1 Year	863.90 (17 Sep 2025)	1,150.10	33.13%
Since IPO	448.00 (issue price)	1,150.10	156.72%

Three-year and five-year figures do not exist: the company listed on 29 December 2023. The 52-week band here runs from Rs 622 to Rs 1,236.10.

Why Did This Contract Manufacturing Pharma Stock Rise 33% in One Year?

Four dated events re-rated this contract manufacturing pharma stock: Jammu turning EBITDA positive, record FY26 revenue reported on 7 May 2026, a strong June quarter announced on 11 August 2026, and a board decision on 22 August 2026 to expand Baddi.

1. The Jammu Plant Stopped Losing Money

Commercial production at Jammu began on 15 January 2025 after more than Rs 450 crore of outlay. Through FY26 the plant dragged on this contract manufacturing pharma stock, absorbing depreciation and interest at low utilisation, which is why FY26 profit grew 10% against 31% revenue growth.

That flipped in the June 2026 quarter. Jammu contributed roughly Rs 107 crore of revenue and turned EBITDA positive at Rs 1 crore to Rs 1.5 crore, against roughly Rs 300 crore for all of FY26. Management put utilisation at 25% to 30% and said the site supports around Rs 1,400 crore of revenue at 65% to 70%.

The plant has four dedicated blocks covering general, cephalosporin, penicillin and penem products, plus a central package including 6% interest subvention on project debt. For a contract manufacturing pharma stock, segregated blocks matter: contamination rules force clients to place such work separately.

2. FY26 Results on 7 May 2026: Highest-Ever Revenue

FY26 revenue from operations came in at approximately Rs 1,630 crore, up 31%, with the March quarter up 42%. EBITDA was approximately Rs 250 crore and net profit approximately Rs 141 crore, the best year on record for this contract manufacturing pharma stock.

The market moved early. The Innova Captab share price gapped from Rs 752 on 30 April 2026 to Rs 844 on 4 May and held it through the results, breaking a six-month range in this contract manufacturing pharma stock.

3. Q1 FY27 on 11 August 2026: Both Engines Fired

June quarter revenue rose 34% to Rs 470.9 crore and net profit 42% to Rs 44.1 crore, with EBITDA of Rs 75.1 crore at a 16% margin. Contract manufacturing revenue was Rs 328.7 crore, up 32%; branded generics Rs 142.2 crore, up 39%.

Volume growth of roughly 22% carried the quarter, with Baddi up 12% to 14% and Jammu the rest; exports were 32% of revenue. This contract manufacturing pharma stock rose about 5.5% on 11 August and touched Rs 1,120 the next session.

4. Approvals and a Rs 45 Crore Baddi Expansion on 22 August 2026

Baddi received UK MHRA certification and Jammu PIC/S recognition, both of which open regulated export markets for a contract manufacturing pharma stock that historically sold into India. It reports over 350 contract manufacturing customers and 4,200 products.

The same day the board cleared a Rs 45 crore brownfield expansion at Baddi, adding two oral solid dosage lines over 18 to 22 months, funded by bank credit and internal accruals. Against the Rs 450 crore Jammu build, that is a low-risk addition for this contract manufacturing pharma stock.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Contract Manufacturing and Domestic Branded Generics: The Real Split

Contract manufacturing is the larger business in this contract manufacturing pharma stock, branded generics the faster-growing one. In the June 2026 quarter it brought in Rs 328.7 crore, roughly 70% of consolidated revenue, against Rs 142.2 crore from branded generics, which grew 51% in FY26.

The two behave differently. Contract manufacturing runs on cost-plus pricing, which protects volumes but caps margins, while branded generics carries the marketing spend and earns a higher gross margin on an asset the company owns.

The client list explains why this contract manufacturing pharma stock trades as a proxy for domestic pharma volumes: it has counted 14 of the top 15 Indian drug makers as customers and says over 80% of revenue comes from long-standing relationships. It also owns Sharon Bio-Medicine, bought out of insolvency in June 2023 for about Rs 195 crore.

What Do the Financials of This Contract Manufacturing Pharma Stock Show?

They show steady growth with margins stuck in a narrow band. Revenue at this contract manufacturing pharma stock compounded from Rs 935.58 crore in FY23 to Rs 1,637.44 crore in FY26, while the operating margin moved between 13.26% and 15.94%.

Metric	Q1 FY27 (Jun 2026)	Q4 FY26 (Mar 2026)	Q1 FY26 (Jun 2025)
Revenue	Rs 472.86 Cr	Rs 449.36 Cr	Rs 356.02 Cr
EBITDA	Rs 75.12 Cr	Rs 66.66 Cr	Rs 56.59 Cr
Operating Margin	15.96%	14.89%	16.09%
Net Profit	Rs 44.13 Cr	Rs 38.08 Cr	Rs 31.02 Cr
Net Margin	9.37%	8.50%	8.82%
Diluted EPS	Rs 7.71	Rs 6.65	Rs 5.42

June 2026 was the best quarter on revenue and profit, yet its 15.96% operating margin sat below the 16.09% a year earlier. That is the tension inside this contract manufacturing pharma stock: scale is arriving faster than profitability.

The balance sheet is conservative for a contract manufacturing pharma stock in expansion mode. FY26 equity was Rs 1,090.79 crore with debt to equity at 0.32, down from 0.73 in FY23. Operating cash flow recovered to Rs 116.52 crore from Rs 63.84 crore, and return on equity is about 12.92%.

On valuation, the Innova Captab share price of Rs 1,150.10 gives a PE of about 42.7 on trailing earnings of Rs 26.92 per share, against an industry PE of about 37.4, and a price to book near 6. A contract manufacturing pharma stock at that premium has to keep delivering 30% growth.

Who Owns This Contract Manufacturing Pharma Stock?

Promoters hold 50.90% of this contract manufacturing pharma stock and have sold nothing across five quarters. Domestic institutions are the dominant non-promoter block at 19.92%, foreign investors a token 0.34%.

Shareholder	Jun 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	50.90%	50.90%	50.90%	50.90%
Domestic Institutions	19.67%	20.24%	20.14%	19.92%
Foreign Investors	0.23%	0.11%	0.23%	0.34%
Public and Others	29.20%	28.76%	28.73%	28.84%

A flat institutional stake suggests the rally in this contract manufacturing pharma stock came from re-rating rather than fresh buying. A credit rating agency reaffirmed it in the A category, positive outlook, in April 2026.

Key Risks in This Contract Manufacturing Pharma Stock

Customer concentration: contract manufacturing is roughly 70% of revenue and the buyers are a small set of large Indian pharmaceutical companies, several of whom run their own plants. If two or three insource a line, revenue moves at once, and cost-plus contracts give this contract manufacturing pharma stock little pricing defence.

Jammu utilisation: the Rs 450 crore facility runs at only 25% to 30% of capacity while its depreciation and interest are fixed. If that stalls, the drag which held FY26 profit growth to 10% persists and the case for this contract manufacturing pharma stock weakens.

Accounting revision: on 22 August 2026 the board approved revised FY26 statements correcting deferred tax errors, lifting consolidated profit by Rs 2.17 crore to Rs 143.18 crore and cutting equity by Rs 10.54 crore. The audit opinion was unmodified, but restating an audited year months later is a governance flag on this contract manufacturing pharma stock.

Input costs: management has flagged rising active ingredient prices and gross margin has already slipped on product mix, and in a cost-plus model the pass-through lags, compressing margins meanwhile.

Liquidity and volatility: market capitalisation is approximately Rs 6,570 crore and volumes run in the tens of thousands of shares on quiet days. On 19 January 2026 the counter traded nearly 17 lakh shares and swung between Rs 624 and Rs 740 in one session. Exit at a chosen price is not assured in a contract manufacturing pharma stock this size, and a regulatory observation at any plant would hit orders and exports.

Download the Univest iOS App or Univest Android App to track the Innova Captab share price live

Innova Captab Share: Analyst View

Coverage on this contract manufacturing pharma stock is thin: the most recent research traceable for this article dates to 2025, and no 2026 note with a target could be verified.

The numbers to watch are those management guides on: Jammu utilisation moving towards 65% to 70%, whether the operating margin climbs back above 16%, and how fast the new approvals convert into orders. FY27 guidance is more than 20% volume growth for this contract manufacturing pharma stock.

Innova Captab Share Price Target

No verified brokerage Innova Captab share price target is available for 2026. The honest reference points for this contract manufacturing pharma stock are the levels the market has set: a high of Rs 1,236.10 on 15 September 2026, a low of Rs 622, and the current Innova Captab share price of Rs 1,150.10.

Annualising the June quarter profit of Rs 44.13 crore gives roughly Rs 176 crore, or about 37 times forward earnings on a market capitalisation near Rs 6,570 crore. Any Innova Captab share price target should start from whether Jammu lifts that run rate, and is an estimate, not a promise.

Other Stocks to Track From the Same Return Screen

Beyond this contract manufacturing pharma stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Graphite India with a 1-year return of 47.08%, Privi Speciality Chemicals at 45.90% and Voltamp at 45.47%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this contract manufacturing pharma stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

This contract manufacturing pharma stock earned its 33% gain in the second half of the year, once Jammu stopped being a pure cost. Record FY26 revenue, a 34% June quarter rise and a Rs 45 crore capacity addition re-rated the Innova Captab share price.

The open questions are as clear. Client concentration, a plant at under a third of capacity, an August 2026 accounting revision and a PE above the industry average sit against that growth. Anyone holding this contract manufacturing pharma stock should watch quarterly utilisation and margin, not the chart.

Frequently Asked Questions

Which contract manufacturing pharma stock rose 33% in 1 year?

Ans. Innova Captab Ltd (NSE: INNOVACAP) is that contract manufacturing pharma stock, up approximately 33% in the year to 17 September 2026, from Rs 863.90 to Rs 1,150.10, with no split or bonus.

What does Innova Captab actually do?

Ans. It manufactures finished formulations for other drug companies and sells its own branded medicines. Contract manufacturing was roughly 70% of June quarter revenue, at Rs 328.7 crore against Rs 142.2 crore from branded generics.

How important is the Jammu facility to Innova Captab?

Ans. Jammu is the single biggest swing factor in this contract manufacturing pharma stock. It began commercial production on 15 January 2025 after more than Rs 450 crore of investment, contributed roughly Rs 300 crore of revenue in FY26 and about Rs 107 crore in the June 2026 quarter, when it turned EBITDA positive.

What were the Q1 FY27 results of Innova Captab?

Ans. Revenue rose 34% to Rs 470.9 crore and net profit 42% to Rs 44.1 crore for the June 2026 quarter, reported on 11 August 2026, with EBITDA of Rs 75.1 crore.

Is customer concentration a risk here?

Ans. Yes, it is the most specific risk in this contract manufacturing pharma stock. Around 70% of revenue comes from making medicines for other pharmaceutical companies, and it has counted 14 of the top 15 Indian drug makers as clients, so losing a few hits revenue.

Why did Innova Captab revise its FY26 financial statements?

Ans. The board approved revised FY26 statements on 22 August 2026 to correct deferred tax errors in this contract manufacturing pharma stock. Consolidated profit rose by Rs 2.17 crore to Rs 143.18 crore and equity fell by Rs 10.54 crore, with an unmodified opinion.

What is the 52-week high and low of the Innova Captab share price?

Ans. The 52-week high is Rs 1,236.10, an intraday print on 15 September 2026, and the low Rs 622 on 2 March 2026. The Innova Captab share price closed at Rs 1,150.10 on 17 September, 7% under that high.

Is there a verified Innova Captab share price target for 2026?

Ans. No verified brokerage Innova Captab share price target for 2026 could be traced for this article. The usable levels for this contract manufacturing pharma stock are the 52-week high of Rs 1,236.10, the low of Rs 622 and a PE near 42.7.